Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients

New Study Published in Journal of Clinical Oncology Supports Universal Genetic Testing for all Breast Cancer Patients

December 10, 2018

Data shows current guidelines exclude many patients with medically relevant genetic changes

Current guidelines for genetic testing of breast cancer patients miss as many patients with pathogenic variants (or genetic mutations) as they find, according to a new study published in the Journal of Clinical Oncology by researchers from the TME Breast Care Network, a network of more than 300 leading breast cancer physicians and Invitae (NYSE: NVTA), one of the fastest growing genetics companies. The findings support broadening and ...

Read more


Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference

Invitae Highlighting New Research, Honoring Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 37th Annual Conference

November 14, 2018

Research highlights frequency of medically actionable variants among secondary findings

Code Talker Award honors excellence in genetic counseling

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, are presenting research at the National Society of Genetic Counselors (NSGC) 37th Annual Conference in Atlanta that further underscores the frequency of medically actionable genetic variants and their utility in clinical care. In addition to its research presentations, the company is supporting the Code Talker award, which recognizes excellence ...

Read more


Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018

Invitae Reports 106% Annual Revenue Growth Driven by 95% Annual Growth in Volume in Third Quarter 2018

November 07, 2018

Raising annual volume and revenue guidance amid strong performance
Q3 2018 gross profit of $16.9M up from nearly $5.0M in Q3 2017
Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the third quarter ended September 30, 2018. Based on progress in the quarter, Invitae is raising its volume guidance from more than 275,000 ...

Read more


Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria

Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria

October 29, 2018

Part of Invitae’s network of partnerships, program supports early diagnosis to help patients and their clinicians make more informed decisions about their health

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to provide genetic testing at no cost to patients through the Alnylam Act® program for individuals who may carry gene mutations associated with primary hyperoxaluria, an ultra-rare genetic disorder affecting ...

Read more


Invitae to announce third quarter 2018 financial results on November 7, 2018

Invitae to announce third quarter 2018 financial results on November 7, 2018

October 24, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number ...

Read more


Research shows high positive rate for risk of hereditary disease in study of  proactive genetic health screening for healthy people

Research shows high positive rate for risk of hereditary disease in study of proactive genetic health screening for healthy people

October 17, 2018

Data presented at annual American Society of Human Genetics meeting 

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, will present findings showing proactive genetic testing identifies medically significant findings for 16.5 percent of healthy individuals. The data add to a growing body of evidence showing expanding clinical genetic testing to people without identified risks could be beneficial.

The platform presentation is among the company’s data being presented this week at The American Society of ...

Read more


Invitae Appoints Chitra Nayak to its Board of Directors

Invitae Appoints Chitra Nayak to its Board of Directors

September 11, 2018

Bringing invaluable expertise in scaling transformative businesses throughout her career as a technology industry veteran 

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced the appointment of Chitra Nayak to its Board of Directors, effective September 10, 2018.

“We are pleased to welcome Chitra Nayak to our board of directors and look forward to working with her, taking full advantage of her considerable track record of helping companies achieve transformational growth to scale and innovate globally,” ...

Read more


Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018

Invitae Reports More than 160% Annual Revenue Growth Driven by Nearly 140% Annual Growth in Volume in Second Quarter 2018

August 07, 2018

Raising annual revenue guidance amid strong quarter performance
Q2 2018 gross profit of $16.9M up from $3.8M in Q2 2017
Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

SAN FRANCISCO, August 7, 2018 Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced financial and operating results for the second quarter ended June 30, 2018. Based on progress in the quarter, Invitae is raising its revenue guidance from ...

Read more


Invitae to announce second quarter 2018 Financial Results on August 7, 2018

Invitae to announce second quarter 2018 Financial Results on August 7, 2018

July 24, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that it will report its second quarter 2018 financial results on Tuesday, August 7, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number ...

Read more


Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening

Invitae Expands Reproductive Health Offering with Launch of Comprehensive Genetic Carrier Screening

June 25, 2018

New Testing Provides Affordable, Accessible Information for Parents-to-Be

 

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the launch of the Invitae Carrier Screen, a comprehensive test designed to provide affordable, accessible information on genetic changes that pose a risk for parents of having a child with an inherited genetic disorder. Each year 7.8 million children worldwide are born with health problems caused at least in part by genetics1.

“By providing affordable, comprehensive ...

Read more